• Work with us
  • External Contractors
Fondazione Toscana Life Sciences
  • IT
  • EN
Toscana Life Sciences
  • THE FOUNDATION
    • Organization
    • History
    • Membership
    • The Legislative Decree No. 231/2001
  • Activity
  • Cluster
  • ITS VITA
  • BIOINCUBATOR
    • Join the Bioincubator
    • Incubated companies
    • Research groups
    • Affiliated companies
  • Services
    • Business development services
    • Research services
    • Incubation services
    • Protection of intellectual property
  • Projects
    • ERC Advanced Grant OMVac
    • Monoclonal Antibody Discovery (MAD) LAB
    • ERC Advanced Grant VACCIBIOME
    • My First AIRC grant @Tumour Immunology Unit
    • Regions4PerMed
    • COSME-AI4DIAG
    • IDF SHARID
    • BORNTOGEtTHERe
    • SINO-EU‐PERMED
    • Orphan diseases
  • Disseminating
    • TLS Open Doors
    • Scientists for a day
    • Science + Economy = Business
    • Researcher’s Night
    • European Biotech Week
  • TLS4Covid19
  • Stories
Enter any keyword and press enter


Greta Immobile Molaro

Chief Executive Officer, Polo GGB



Download Watch video


Looking to gain time


Polo GGB

Studying the uniqueness of all living things


The medical revolution is already underway and classic diagnosis and treatment approaches have been overtaken by a new vision based on the great genetic variability of each individual. It’s our uniqueness, the more accurate characterization of each single genomic background and how it influences the predisposition to the diseases or the effectiveness of drugs, that takes shape the precision medicine. Polo GGB, a non-profit company recently incubated in Tuscany Life Sciences Foundation, operates in this field. Polo GGB has built a strong expertise in a variety of sequencing applications in all fields of life sciences like Whole Genome, De-Novo, Whole Transcriptome, miRNA, Exome, Methylation, Ribosome profiling, Targeted RNA and relative libraries preparation (including Mate-Pair). Moreover, Polo GGB provides bioinformatics analysis for all the sequencing applications. The facility holds some of the most advanced instruments in the field including HiSeq 2500 Illumina, MiSeq DX Illumina, MiSeq Illumina. The computational infrastructure consists of high throughput computing servers and high storage capacity appliances. The main objectives, as underlined by CEO Greta Immobile Molaro in the interview, are driving innovation in genetics and genomics and promoting technology transfer with industry. From the entrance in the bio-incubator, the company is actively contributing to precision medicine projects, in collaboration with the TLS, public and private research institutions and enterprises.

Read more

VISMEDERI

Checking the quality of vaccines and food
read more


KEDRION BIOPHARMA

Finding a cure for even one patient
read more


PHARMA INTEGRATION

The new robots in the land of Leonardo
read more


Fondazione NIBIT

Identifying innovative strategies against cancer
read more


Fondazione Toscana Life Sciences
Via Fiorentina, 1
53100 Siena – ITALIA

  • tel +39 0577 231211
  • fax +39 0577 43444
  • info@toscanalifesciences.org; info@pec.fondazionetls.org

Twitter Feeds

In attesa del collegamento con #NewsRoom di RaiNews qualche scatto del backstage 📷 dell'intervista del Direttore Ge…

@FondazioneTLS 4 Hours Ago

Continua il viaggio di @RaiNews tra le aziende del nostro bioincubatore. 📷 Qualche scatto della visita in…

@FondazioneTLS 6 Hours Ago

Ecco qualche scatto della visita di oggi di @RaiNews alla Fondazione Toscana Life Sciences per raccontare l'esperie…

@FondazioneTLS 9 Hours Ago

Contatti

    Concedo il consenso al trattamento dei dati personali secondo la nostra Privacy Policy per poter essere contattato da Fondazione Toscana Life Sciences.

©2015-2019 - Fondazione Toscana Life Sciences - P.I. 01194710529 - Codice SDI: SUBM70N - Privacy - Cookie Policy